Impact of hemoperfusion with polymyxin B added to hemofiltration in patients with endotoxic shock: a case–control study

Annals of Intensive Care

Table 2 Type of infection, microbiology findings, and initial empiric antibiotic treatment

	Sepsis focus	Microbiology findings	Empiric antibiotic treatment
Control patients
Patient 1	Urinary tract	Negative	Meropenem plus vancomycin plus caspofungin
Patient 2	Urinary tract	Escherichia coli	Piperacillin–tazobactam
Patient 3	Urinary tract	Escherichia coli	Meropenem
Patient 4	Biliary tract	Escherichia coli/Enterococcus faecalis, Enterococcus faecium	Meropenem plus vancomycin
Patient 5	Peritonitis	Escherichia coli	Meropenem plus vancomycin
Patient 6	Peritonitis	Mixed flora	Meropenem plus amikacin
Patient 7	Biliary tract	Escherichia coli	Meropenem
Patient 8	Peritonitis	Negative	Meropenem
Patient 9	Peritonitis	Enterococcus faecium, Candida albicans, Candida tropicalis	Meropenem plus vancomycin plus anidulafungin
Toraymyxin treated patients
Patient 1	Urinary tract	Escherichia coli	Meropenem plus vancomycin
Patient 2	Peritonitis	Escherichia coli/Enterococcus faecium/Bacteroides fragilis	Piperacillin–tazobactam plus fluconazole
Patient 3	Biliary tract	Escherichia coli/Streptococcus anginosus	Piperacillin–tazobactam plus fluconazole
Patient 4	Peritonitis	Escherichia coli	Piperacillin–tazobactam plus fluconazole
Patient 5	Biliary tract	Escherichia coli	Meropenem
Patient 6	Peritonitis	Mixed flora	Piperacillin–tazobactam
Patient 7	Peritonitis	Negative	Piperacillin–tazobactam
Patient 8	Urinary tract	Escherichia coli	Meropenem
Patient 9	Peritonitis	Mixed flora	Piperacillin–tazobactam